BEIJING, Oct. 19 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today announced its 2010 growth strategy.
Lotus's priorities for the balance of 2009 are 1) deciding what the Company needs to do for its most valuable customers and continuing on its efforts, and 2) identifying new product and market demand, and 3) preparing for the construction of a new office building on the ground of its existing plant so that operational efficiency could be achieved by moving the separate units of sales, production and R&D bases into one single location. This has been made possible because the government approved the zoning right of Lotus's property in Beijing to upgrade to industrial use in June of 2009. Lotus is permitted to build gross floor areas of 20,353 square meters in four-nine floors above the ground and one floor underground.
Dr. Zhong Yi Liu, Chairman and CEO of Lotus commented, "Based on the past two years of business expansion, we currently believe that we will achieve our financial goals for the year 2009 and grow steady in the year of 2010." The Company's growth plan for the next year, includes, but is not limited to the following areas:
Expand Sales Network. Lotus currently plans to add 15-20 more distributors by the end of 2010 to its nation-wide sales channels. Lotus attends substantially every major drug expos in China. Lotus's sales representatives are experienced with medical education backgrounds, and are located in ten regional sales centers providing sales and post-sales services to its customers. Regional distributors come into contact with Lotus through words of mouth and public information.
|SOURCE Lotus Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved